Search Bar & Filters
Found 19 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety, effectiveness, and lasting effects of a single intravitreal injection of 4D-150 compared to aflibercept in adults with diabetic macular edema DME. The study is a Phase 3, randomized, double-masked, active-controlled trial designed to assess visual acuity changes and disease severity over one year. Participants will be randomly assigned to receive either a single dose of 4D-150 or aflibercept eye injections. The 4D-150 treatment is given once on Day 1, while aflibercept is administered at appropriate visits. The study lasts for 52 weeks, focusing on visual outcomes and the need for additional aflibercept injections after the initial treatments. Throughout the study, participants will undergo regular eye examinations to monitor visual acuity using the Early Treatment Diabetic Retinopathy Study ETDRS scale and assessments of diabetic retinopathy severity. Researchers will also track the number of aflibercept injections needed after Week 4. Safety and durability of the treatments will be closely observed during the one-year follow-up period.
Actively Recruiting
Researchers are studying the effectiveness, safety, and tolerability of combining elecoglipron and dapagliflozin compared to using each drug alone in adults with type 2 diabetes mellitus T2DM who are not well controlled by lifestyle changes or other diabetes medications. This phase III trial aims to understand how well these treatments manage blood sugar levels in this population. Participants will be randomly assigned to one of five groups two different doses of elecoglipron combined with dapagliflozin, two doses of elecoglipron combined with a placebo matching dapagliflozin, or dapagliflozin alone with a placebo matching elecoglipron. All medications are taken orally once daily. The study uses a double-blind, parallel-group design to compare these treatments over 40 weeks. During the study, participants will have their blood sugar control measured primarily by changes in Hemoglobin A1c HbA1c from the start to week 40. Secondary measures include body weight changes, fasting plasma glucose, blood pressure, and time to starting rescue medication. Regular assessments will monitor safety and treatment effects throughout the trial period, which lasts about 40 weeks.
Actively Recruiting
Researchers are evaluating the effect of a transdermal formulation called SFG-02 on Bladder Voiding Efficiency BVE in adults with Underactive Bladder UAB. This Phase 2a proof-of-concept study aims to assess both the impact on bladder function and the safety of the treatment compared to a placebo. Participants have symptoms like urinary hesitancy, straining to void, or weak urinary stream and meet specific bladder function criteria. Participants will undergo a 4-week placebo run-in period followed by 8 weeks of daily application of either the SFG-02 patch or a placebo patch. Each patch is worn for a full day, and participants will apply a new patch every day for a total treatment duration of 12 weeks. The study uses a randomized, double-blind design to compare the active drug to placebo. During the study, participants will visit the clinic every 2 to 4 weeks for checkups and tests. They will keep diaries to record bladder symptoms and the timing of patch changes. Researchers will monitor changes in Bladder Voiding Efficiency from baseline to the end of treatment as the primary outcome. Safety will also be assessed through laboratory tests and heart monitoring, with the entire participation lasting approximately 12 weeks.
Actively Recruiting
Researchers are evaluating the effects of AZD6234 as an additional treatment alongside incretin-based therapies in adults who are overweight or have obesity with at least one weight-related health condition, with or without Type 2 Diabetes Mellitus. This Phase III global study will compare how well AZD6234 works against a placebo by measuring changes in body weight over 68 weeks. Participants will be randomly assigned to receive either AZD6234 or a matching placebo, both given as weekly injections under the skin. These treatments will be added to their stable dose of existing incretin-based medications. The study is designed to monitor participants for 68 weeks of treatment to assess the impact on body weight and related health measures. During the study, participants will undergo regular assessments including body weight measurements, waist circumference, blood pressure, blood tests for triglycerides and HbA1c, and evaluation of weight loss milestones. Safety and effectiveness will be closely monitored throughout the treatment period, which lasts about 68 weeks. The study aims to provide detailed information on how AZD6234 affects weight and metabolic health in this population.
Actively Recruiting
Researchers are evaluating the effectiveness, safety, and tolerability of elecoglipron compared with oral semaglutide in adults with type 2 diabetes mellitus T2DM who have an increased cardiovascular risk. This study focuses on patients whose diabetes is not adequately controlled with lifestyle changes or stable glucose-lowering medications. The trial is a Phase III, randomized, open-label, parallel-group study sponsored by AstraZeneca. Participants will be randomly assigned to receive either elecoglipron or semaglutide, both administered orally once daily at specified doses. The treatment period lasts up to 52 weeks, during which the effects of these medications on blood sugar control and other health measures will be assessed. Throughout the study, participants will undergo regular evaluations including measurements of hemoglobin A1c HbA1c, body weight, and blood pressure at baseline and at 52 weeks. Researchers will monitor changes in these parameters to assess the impact of the treatments. Safety and tolerability will also be closely followed during the trial period.
Actively Recruiting
Researchers are evaluating the cardiovascular outcomes of elecoglipron compared with a placebo in adults with heart failure with preserved ejection fraction HFpEF or mildly reduced ejection fraction HFmrEF. This Phase III, randomized, double-blind, placebo-controlled study includes participants regardless of type 2 diabetes status who are also taking dapagliflozin along with other standard care treatments. Participants are randomly assigned to receive either elecoglipron tablets once daily or matching placebo tablets once daily. The study is conducted across multiple centers and follows a parallel-group design. The treatment period may last up to 42 months, during which the effects of elecoglipron on cardiovascular events and patient outcomes are assessed. Throughout the study, participants undergo regular evaluations to monitor their heart failure status, including assessments of cardiovascular death risk, hospitalization for heart failure, and urgent heart failure visits. Patient-reported outcomes are collected using questionnaires at baseline and at 52 weeks. Safety and efficacy are closely monitored over the extended treatment period to determine the impact of elecoglipron compared to placebo.
Actively Recruiting
Researchers are evaluating the safety and effects of berobenatide PF-08653944 in adults with obesity disease, a condition characterized by excess body fat that can harm health and increase the risk of other medical problems. Some participants may also have type 2 diabetes, where the body does not use insulin properly, leading to high blood sugar levels. This Phase 3 clinical trial is being conducted in Japan to better understand how berobenatide works for people with these conditions. Participants will be randomly assigned to receive either berobenatide or a placebo. Both treatments are given as injections under the skin of the abdomen once a week. The study compares the effects of berobenatide to placebo in helping people lose weight and examines its safety. About 180 adults will participate, and the study includes up to 15 in-person visits and 2 phone visits over approximately 22 months. During the study, participants will have their body weight and waist circumference measured, along with blood pressure and blood tests to check glucose, insulin, cholesterol, and inflammation markers. Questionnaires about quality of life related to weight will also be completed. Researchers will monitor for any side effects or adverse events. The main outcome is the percent change in body weight from the start to week 72, with other health measures also tracked throughout the trial.
Actively Recruiting
Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults with chronic heart failure who have a reduced left ventricular ejection fraction below 40%. Participants must have been diagnosed with chronic heart failure for at least three months and be in New York Heart Association classes II to IV. The study is a phase III, randomized, double-blind trial aimed at assessing whether this combination improves outcomes compared to placebo plus empagliflozin. Participants are randomly assigned to one of two groups with equal chance one group receives vicadrostat with empagliflozin tablets, and the other receives placebo with empagliflozin tablets. The study medicines are taken once daily for about six months up to three and a half years. Participants continue their regular heart failure treatments alongside the study drugs. The study monitors participants throughout this period, which can last up to 43 months. During the study, participants attend regular visits to the study site and may receive some follow-up calls. They answer questionnaires about their symptoms and overall well-being. Doctors record any worsening heart failure symptoms, hospitalizations due to heart failure, or deaths to compare the two groups. Health status and any side effects are regularly checked. The primary outcome is the time to first cardiovascular death, hospitalization for heart failure, or urgent heart failure visit.
Actively Recruiting
Researchers are evaluating the combination of vicadrostat BI 690517 and empagliflozin for adults aged 18 and older who have heart failure symptoms and a left ventricular ejection fraction LVEF of 40% or more. The study aims to find out whether taking vicadrostat with empagliflozin helps people with heart failure. This is a phase III randomized, double-blind, parallel-group trial sponsored by Boehringer Ingelheim. Participants are randomly assigned to one of two groups one group takes vicadrostat combined with empagliflozin tablets once daily, and the other group takes a placebo combined with empagliflozin tablets once daily. The study has no fixed duration participants can stay in the study as long as they benefit from treatment and can tolerate it. During the study, participants visit their doctors regularly for health checks and monitoring. Throughout the study, participants undergo regular health assessments including monitoring for any unwanted effects. Study staff may also contact participants by phone and ask them to answer questions about their well-being. The main outcome being measured is the time to the first event of cardiovascular death, hospitalization for heart failure, or urgent heart failure visit over up to 42 months. Other outcomes include symptom scores, blood pressure changes, and kidney function. The study runs until enough data is collected to evaluate the treatments effects.
Actively Recruiting
Researchers are evaluating the effects of muvalaplin in reducing the risk of major cardiovascular events in adults with elevated lipoproteina levels who either have cardiovascular disease or are at risk for a heart attack or stroke. This Phase 3, randomized, double-blind, placebo-controlled study focuses on adults with high lipoproteina and a history or risk of atherosclerotic cardiovascular events. The study aims to better understand if muvalaplin can lower the occurrence of serious heart-related problems. Participants will be randomly assigned to receive either muvalaplin or a placebo, both taken orally. The study compares these two groups over about 5.25 years to assess the impact of muvalaplin on major adverse cardiac events. The research includes ongoing monitoring of lipoproteina levels and other cardiovascular outcomes throughout this period. During the study, participants will undergo regular assessments including measuring changes in lipoproteina, tracking the time to occurrence of major cardiovascular events, and monitoring overall health outcomes. Researchers will collect data on healthcare resource usage and drug levels in the body. The long-term follow-up allows for thorough evaluation of muvalaplins effects on heart health and safety over more than five years.
1-10 of 19
1